Ablynx submits a marketing authorisation application to the European Medicines Agency for Caplacizumab, for the treatment of aTTP. If approved, it will be the first therapeutic specifically indicated for the treatment of aTTP.
What is the study about? In partnership with the National Organization for Rare Disorders, this will be the first large-scale study about the information and psychosocial support needs of people living with rare disorders in the US. The purpose of this research study is to assess these needs, from the perspectives of people with a variety of rare disorders, to find similarities and differences across disorders.
A paper on PTSD and depression in TTP survivors was recently accepted for publication in Thrombosis Research. The study was conducted by a Clinical Fellow of Vanderbilt University Medical Center, Shruti Chaturvedi. Answering TTP Foundation spread the word about this very important research. Thank you to those who took part. There is more work to do. Register for the Answering TTP Community to receive invitations and updates like these.
Hello, thank you for having me participate today. I am sorry that I was unable to make the journey to be there in person. Unfortunately this was impossible due to my health. I have TTP and also Stage IV Melanoma as a result of my treatment. Let me start with a little about me…
Over $1.5 million committed to research grants through 2018.
Answering TTP Foundation understands the need for biomedical, clinical and population health research and accepts research proposals internationally. We are excited to announce the funding of three new promising international resesarch grants beginning September 2016.
The Meeting Report from the TTP Dinner Symposium on June 23, 2015 was published online on June 8, 2016 (ahead of print) by the Expert Review of Hematology journal. Authors: Pavenski K, Cataland S, Kremer Hovinga J, Thomas M, Vanhoorelbeke K. Congratulations to the authors.